Roche GO42784 (TRIO 045 "lidERA")

Breast - lidERA

Roche GO42784 (TRIO 045 "lidERA")

Objective

Phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant GIREDESTRANT compared with physician's choice of adjuvant endocrine monotherapy in patients with ER positive, Her-2 neg early breast cancer *must be medium or high risk for recurrence

Principal Investigator(s)
David Chan, MD

Clinical Trial Categories

  • UCLA Trio Clinical Trials